31 October 2022 has been confirmed as the last date at which patients globally may be entered into screening for the trial. All patients screened on or prior to 31 Oct 2022 will continue in the study as usual i.e. eligibility review, induction chemotherapy, MTB (if applicable) and Treatment phase.